Moderna (MRNA)
(Delayed Data from NSDQ)
$142.55 USD
-8.94 (-5.90%)
Updated May 31, 2024 04:00 PM ET
After-Market: $142.25 -0.30 (-0.21%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MRNA 142.55 -8.94(-5.90%)
Will MRNA be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for MRNA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MRNA
The Zacks Analyst Blog Highlights NVIDIA, Constellation Energy, Micron Technology, Moderna and Qualcomm
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
MRNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nasdaq Tops 17K: 5 Best-Performing Stocks in ETF YTD
Moderna (MRNA) Stock Outperformed Industry YTD: Here's Why
Vaccine Stocks Rise on Growing Threat of Bird Flu Infections
Other News for MRNA
Buy Rating Affirmed for Moderna on Mresvia’s RSV Vaccine Prospects and Anticipated ACIP Endorsement
Moderna price target raised by $25 at RBC Capital, here's why
US approves Moderna's RSV vaccine for older adults
10 Health Care Stocks Whale Activity In Today's Session
Moderna wins second product approval with RSV vaccine